


## Tipiracil

<b>Cat. No.:</b>	HY-A0063A		
<b>CAS No.:</b>	183204-74-2		
<b>Molecular Formula:</b>	C <sub>9</sub> H <sub>11</sub> ClN <sub>4</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	242.66		
<b>Target:</b>	Thymidylate Synthase; Nucleoside Antimetabolite/Analog		
<b>Pathway:</b>	Apoptosis; Cell Cycle/DNA Damage		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 1 mg/mL (4.12 mM; Need ultrasonic and warming)  
 H<sub>2</sub>O : 1 mg/mL (4.12 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	4.1210 mL	20.6050 mL	41.2099 mL
5 mM	---	---	---
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

1. Add each solvent one by one: PBS  
 Solubility: 2 mg/mL (8.24 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

### BIOLOGICAL ACTIVITY

#### Description

Tipiracil is a thymidine phosphorylase (TPase) inhibitor.

#### IC<sub>50</sub> & Target

thymidine phosphorylase<sup>[1]</sup>

#### In Vitro

Tipiracil is an inhibitor of thymidine phosphorylase. Tipiracil increases trifluridine exposure by inhibiting its metabolism by thymidine phosphorylase. The combination of Trifluridine and Tipiracil is a new oral treatment for metastatic colorectal cancer<sup>[2]</sup>. Tipiracil prevents degradation of FTD through a first-pass effect as a thymidine phosphorylase inhibitor<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Cell Assay<sup>[3]</sup>

HeLa cells are seeded in 96-well plates at 500 cells/180  $\mu$ L/well in triplicate, pre-cultured for 24 h, and then 20  $\mu$ L of each drug solution is added for 24 or 72 h. For the 24 h treatment, cells are washed with phosphate-buffered saline (PBS) after treatment, drug-free medium is added to each well, and the culture is further incubated for 48 h. Cell growth inhibition is evaluated using a Cell Counting Kit-8. The 50% inhibitory concentration ( $IC_{50}$ ) values are calculated from the absorbance data using SAS<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Animal Administration<sup>[3]</sup>

#### Mice<sup>[3]</sup>

For experiments, 8 mm<sup>3</sup> cubic fragments of tumor are implanted subcutaneously into the axilla of mice. For preparation of the orally administered FTD solution, FTD is dissolved in a 0.5% aqueous solution of hydroxypropyl methyl-cellulose (HPMC). The FTD solution for continuous infusion is prepared by dissolving FTD in physiological saline. The TAS-102 dosing solution is composed of FTD and TPI dissolved in a 0.5% aqueous solution of HPMC at a molar ratio of 1:0.5. The dose of TAS-102 is expressed on the basis of the amount of FTD. For preparation of the S-1 solution, FT, CDHP and Oxo are dissolved in a 0.5% aqueous solution of HPMC at a molar ratio of 1:0.4:1. The dose of S-1 is expressed on the basis of the amount of FT. When the tumor volume reaches 100 mm<sup>3</sup>, the mice are randomly assigned into different treatment groups. Nude mice in the treatment group receive the test compounds. The control group receive no treatment. For continuous infusion, the compound is administered with an osmotic pump. Tumor volume is measured twice a week throughout the experiments. Tumor volume and relative tumor volume are calculated. Body weight changes (BWCs) are used as a proxy measure of side-effects, and calculated. The tumor growth inhibition rate (IR) % on day 15 is used to quantify the antitumor effect.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Biomed Pharmacother. 2021 May 6;139:111672.
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
- Oncol Rep. 2023 Mar;49(3):52.
- Mod Rheumatol. 2018 May;28(3):495-505.
- Patent. US Patent 11110111.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Lee SJ, et al. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1327-35.
- [2]. Raedler LA. Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):97-100.
- [3]. Tanaka N, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014 Dec;32(6):2319-26.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA